IPSEN – Sponsored Industry Symposium Highlights

In the Ipsen satellite symposium, Professor Sandrine Faivre will take us through the rapidly evolving HCC treatment landscape, with a look at clinical studies approaching completion in the near future, such as HIMALAYA, LEAP-002 and COSMIC-312. Leveraging her extensive clinical experience alongside the latest data, Professor Faivre will explain how to select the optimal treatment for patients and how newly approved treatments may integrate into the landscape.  

Professor Arndt Vogel will discuss sequence combinations across various trials including CELESTIAL (cabozantinib) and RESORCE (regorafenib). Using his expert insight, Prof. Vogel will explain his decision-making around 2nd-line therapy selection, whether following tyrosine kinase inhibitor (TKI) or checkpoint inhibitor therapy.

Professor Josep Llovet will conclude the discussion with insights from the tumour microenvironment and highlight synergies between various treatment combinations with respect to ongoing trials; for example, COSMIC-312 (cabozantinib plus atezolizumab) and LEAP-002 (lenvatinib plus pembrolizumab).

Other highlights include Catherin Willoughby’s presentation on pre-clinical data on the synergy that can be found between TKI and anti-PD1 therapies (O-04: ‘Cabozantinib Enhances The Efficacy And Immune Activity Of Anti-Pd1 Therapy In A Murine Model Of Hepatocellular Carcinoma’). Additional information on this topic comes in the form of a poster presented by Laura Torrents (P-76: Immune-Remodeling Effects Of Lenvatinib Plus Anti-PD1 In A Murine Model Of Hepatocellular Carcinoma).

There are of course, many other fascinating discussions to be heard over the next few days, and we look forward to the many exciting and interesting presentations to come at ILCA Conference 2020.

This is an educational, non-promotional meeting organised and funded by Ipsen. The opinion and views expressed in this presentation are those of the presenter and do not necessarily constitute the opinions or recommendations of Ipsen (i.e. The scientific information may include data/information on drugs that have not yet received price and reimbursement approval by local regulatory authorities. Reimbursement conditions for this product may differ from country to country, please check these out for the country where you are a prescriber)


CBZ-BE-000442/CBZ-ALL-002209 Date of preparation: September 2020